期刊文献+

1,4-二[3-(氨基硫代甲酰硫基)丙酰基]哌嗪类化合物的合成及其抗肿瘤活性 被引量:6

SYNTHESIS AND ANTI-TUMOR ACTIVITIES OF 1,4 BIS[3- (AMINO-DITHIOCARBOXY)PROPIONYL] PIPERAZINE DERIVATIVES
下载PDF
导出
摘要 目的 寻找并合成低毒、有较强抗肿瘤活性的哌嗪类化合物。方法和结果 以 1,4 二 (3 溴丙酰基 )哌嗪为先导物 ,合成了一系列 1,4 二 [3 (氨基硫代甲酰硫基 )丙酰基 ]哌嗪类新化合物 ,并测试了这些化合物 (4a - j)对 8种瘤细胞株的体外抗肿瘤活性。结论 体外抗肿瘤活性试验结果表明 ,大多数化合物显示一定的抗肿瘤活性 ,尤其是化合物 4c,4d和 4e,浓度在 10 μmol·L-1时 ,对HL 6 0细胞抑制率分别为 44 % ,90 %和 70 %。 AIM To synthesize piperazine derivatives and screen anti tumor compounds with higher activity and lower toxicity. METHODS Selecting 1,4 bis(3 bromopropionyl)piperazine as leading compound, a series of 1,4 bis[3 (amino dithiocarboxy)propionyl] piperazine derivatives (4a-j) were synthesized through the use of aminodithiocarboxylate. All the synthetic compounds (4a-j) were tested for their anti tumor activity against eight kinds of tumor cells. RESULTS Compounds (4a-j) are new compounds, among them, compounds 4c, 4d and 4e showed anti tumor activity against HL 60. The inhibition of compounds 4c, 4d and 4e against HL 60 are 44%, 90% and 70% respectively, at the concentration of 10 μmol·L -1 . However, the inhibition of the other kinds of anti tumor cells are not distinctive. CONCLUSION These results suggest that this may be one of the effective routes to improve the anti tumor activity and reduce the toxicity of 1,4 bis(3 bromopropionyl)piperazine.
机构地区 北京大学药学院
出处 《药学学报》 CAS CSCD 北大核心 2001年第3期185-187,共3页 Acta Pharmaceutica Sinica
关键词 1 4-二[3-(氨基硫代甲酰硫基)丙酰基]哌嗪 抗肿瘤活性 合成 bis(3-bromopropionyl)piperazine 1,4-bis[3-(amino-dithiocarboxy) propionyl]piperazine derivatives anti tumor activity
  • 相关文献

参考文献6

  • 1Ge Z M,Synth Commun,1999年,29卷,18期,3191页
  • 2Li R T,Synth Commun,1999年,29卷,1期,65页
  • 3Li R T,高等学校化学学报,1999年,20卷,12期,1897页
  • 4Li R T,Synth Commun,1998年,28卷,2期,295页
  • 5Gerhauser C,Cancer Res,1997年,57卷,2期,272页
  • 6Ge Z M,Eur J Med Chem

同被引文献17

  • 1姜小梅,凌笑梅,李润涛,崔景荣.HPLC-ESI/ITMS^n法分析大鼠体内4-甲基哌嗪-1-二硫代甲酸-(3-氰基-3,3-二苯基)丙酯盐酸盐及其主要代谢物[J].药学学报,2006,41(11):1084-1089. 被引量:3
  • 2Curtin NJ,Hughes AN.Pemetrexed disodium,a novel antifolate with multiple targets[J].Lancet Oncol,2001,2:298-306.
  • 3Marsham PR,Hughes LR,Jackman AL,et al.Quinazoline antifolate thymidylate synthase inhibitors:heterocyclic benzoyl ring modifications[J].J Med Chem,1991,34:1594-1605.
  • 4Cunningham D,Zalcberg J,Maroun J,et al.Efficacy,tolerability and management of raltitrexed monotherapy in patients with advanced colorectal cancer:a review of phase II/III trials[J].Eur J Cancer,2002,38:478-486.
  • 5Webber S,Bartlett CA,Boritzki TJ,et al.AG337,a novel lipophilic thymidylate synthase inhibitors:in vitro and in vivo preclinical studies[J].Cancer Chemother Pharmacol,1996,37:509-517.
  • 6Marsham PR,Wardleworth JM,Boyle FT,et al.Design and synthesis of potent non-polyglutamatable quinazoline antifolate thymidylate synthase inhibitors[J].J Med Chem,1999,42:3809-3820.
  • 7Creaven PJ,Pendyala L,Meropol NJ,et al.Initial clinical trial and pharmacokinetics of ThymitaqTM (AG337) by 10-day continuous infusion in patients with advanced solid tumors[J].Cancer Chemother Pharmacol,1998,41:167-170.
  • 8Chu E,Callender MA,Farrell MP,et al.Thymidylate synthase inhibitors as anticancer agents:from bench to bedside[J].Cancer Chemother Pharmacol,2003,52:S80-S89.
  • 9Mehta RG,Liu J,Constantinou A,et al.Cancer chemopreventive activity of brassinin,a phytoalexin from cabbage[J].Carcinogenesis,1995,16:399-404.
  • 10Güzel O,Salman A.Synthesis,antimycobacterial and antitumor activities of new (1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)methyl N,N-disubstituted dithiocarbamate/O-alkyldithiocarbonate derivatives[J].Bioorg Med Chem,2006,14:7804-7815.

引证文献6

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部